CELZ 226m OS stem cell patent bio. ran to 014 not too long ago, next run is bigger
CELZ is at the final stage of the clinical Phase IV studies,--- often called Post Marketing Surveillance Trials, are conducted after a drug / procedure / device has been approved for consumer sale.
Pharmaceutical companies have several objectives at this stage:
(1) to compare a drug with other drugs already in the market;
(2) to monitor a drug's long-term effectiveness and impact on a patient's quality of life; and
(3) to determine the cost-effectiveness of a drug therapy relative to other traditional and new therapies.
This is also the most costly phase of R& D Human Clinical Trial Phases..
IT NEEDS TO RAISE CAPITAL TO COMMERCIALIZE ITS PRODUCTS/ PATENTS.
----That is why CELZ has applied for special exception Confidential Treatment Order ( C.T.O.)--The reason is to omit certain information from their required filings they can complete a confidential treatment order request, which is reviewed by the SEC. The request must contain the information the company is looking to withhold and the time period the company is looking to withhold the information.
Companies would typically seek a confidential treatment order (CTO) to keep information secret that would otherwise put it at a competitive disadvantage if revealed. A company would seek the confidential treatment order by filing a formal request, a confidential treatment request (CTR), with the Securities and Exchange Commission (SEC).
The Company has acquired a royalty license from Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (“LABIOMED”) granting the exclusive license to the products and services of a LABIOMED patent.
Creative Medical is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility and related issues. It holds a patent for its erectile dysfunction ("ED") treatment and was granted a license by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, a non-profit biomedical research and education institute ("LABIOMED"), for the infertility treatment. It has also filed a patent application focused on physical manifestations of female sexual arousal disorder, as an extension of the work with stem cell therapies for ED. Following testing of its ED treatment, Creative Medical intends to market treatment kits to physicians for use with their patients suffering from ED.
During first quarter 2016, it commenced a 15-month clinical trial study being conducted at UCLA by LABIOMED on the efficacy and safety of the ED treatment. The study involves testing on 40 subjects. Following further testing, Creative Medical also intends to market licensed products under its infertility technology license and the female sexual dysfunction patent application.<-----PHASE 4
The increase of A/S is to raise capital. At the same time, when completion, most likely to merge/bought (out) by/with other medical/pharmaceutical company or to sell the rights to venture capital group.
We are getting really close to completion.
Basically, it can be any time to hear another update or PR soon when enough funds have been raised.
More DD...
Filing Date Document Date Type Category Amended
03/02/2018 01/05/2018 8-K Special Events
02/23/2018 02/22/2018 8-K Special Events
02/01/2018 02/01/2018 8-K Special Events
01/31/2018 01/08/2018 DEF 14C Proxy Statement
01/16/2018 01/12/2018 8-K Special Events
01/12/2018 01/12/2018 PRE 14C Proxy Statement
01/12/2018 01/09/2018 8-K Special Events
01/04/2018 12/29/2017 8-K Special Events
12/20/2017 12/20/2017 8-K Special Events
12/18/2017 12/18/2017 8-K Special Events
12/18/2017 N/A SC 13G/A Institutional Ownership *
12/13/2017 12/13/2017 8-K Special Events
11/17/2017 11/17/2017 8-K Special Events
11/16/2017 11/14/2017 8-K Special Events
11/13/2017 09/30/2017 10-Q Quarterly Reports
10/18/2017 10/18/2017 8-K Special Events
10/12/2017 10/11/2017 8-K Special Events
08/28/2017 08/28/2017 8-K Special Events
08/14/2017 06/30/2017 10-Q Quarterly Reports
07/25/2017 07/25/2017 8-K Special Events
YES WE ARE DOWN FOR NOW
WE ARE NOT OUT.
